8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Preference for daily versus on‐demand pre‐exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real‐world Oral PrEP Demonstration study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          This study explores the preference for daily versus on‐demand pre‐exposure prophylaxis (PrEP) among men who have sex with men (MSM) in developing countries when both regimens are available.

          Methods

          From 11 December 2018 to 19 October 2019, we recruited MSM for an open‐label real‐world PrEP demonstration study in four major cities in China. Subjects selected their preferred PrEP (oral tenofovir/emtricitabine) regimen (daily vs. on‐demand) at recruitment and underwent on‐site screening before initiation of PrEP. We used logistic regression to assess preference for daily PrEP and correlates.

          Results

          Of 1933 recruited MSM, the median age was 29 years, 7.6% was currently married to or living with a female; the median number of male sexual partners was four and 6.1% had used post‐exposure prophylaxis (PEP) in the previous six months. HIV infection risk was subjectively determined as very high (>75%) in 7.0% of subjects, high (50% to 75%) in 13.3%, moderate (25% to 49%) in 31.5% and low or none (0% to 24%) in 48.1%. On average, participants preferred on‐demand PrEP over daily PrEP (1104 (57.1%) versus 829 (42.9%)) at recruitment. In multivariable analysis, currently being married to or living with a female was associated with 14.6 percentage points lower preference for daily PrEP (marginal effect = −0.146 [95% CI: −0.230, −0.062], p = 0.001); whereas the number of male sexual partners (marginal effect = 0.003 [95% CI: 0.000, 0.005], p = 0.034) and a subjective assessment of being very high risk of HIV infection (vs. low and no risk, marginal effect size = 0.105 [95% CI: 0.012, 0.198], p = 0.027) were associated with increased preference for daily versus on‐demand PrEP. Among the 1933 potential participants, 721 (37.3%) did not attend the subsequent on‐site screening. Lower‐income, lower education level, lower subjective expected risk of HIV infection risk and younger age positively correlated with the absence of on‐site screening.

          Conclusions

          MSM in China prefer both daily and on‐demand PrEP when both regimens are provided free. Social structural factors and subjective risk of HIV infection have significant impacts on PrEP preference and use. The upcoming national PrEP guideline should consider incorporating both regimens and the correlates to help implement PrEP in China.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

          Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57). Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

            Summary Background Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect. Methods PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). Findings We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1·2/100 person-years) versus 20 in the deferred group (9·0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64–96, p=0·0001; absolute difference 7·8/100 person-years, 90% CI 4·3–11·3). 13 men (90% CI 9–23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients. Interpretation In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection. Funding MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

              Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of adherence to a daily regimen.
                Bookmark

                Author and article information

                Contributors
                zhangjing1985zj@163.com
                xjjcmu@163.com
                lupinhy@163.com
                huangxiaojie78@126.com
                yaokaichen@hotmail.com
                jimmy114337@163.com
                laochu323@163.com
                qinghaihucn@163.com
                dr.hexiaoqing@foxmail.com
                yaoli0823@hotmail.com
                zlkdermatology@sina.com
                18835168738@163.com
                brtcmu@163.com
                lsccmu@163.com
                lihang0423lh@163.com
                ding_haibo@126.com
                jiangjun55555@163.com
                windygeng@163.com
                sean_sylvia@unc.edu
                hongshang100@hotmail.com
                Journal
                J Int AIDS Soc
                J Int AIDS Soc
                10.1002/(ISSN)1758-2652
                JIA2
                Journal of the International AIDS Society
                John Wiley and Sons Inc. (Hoboken )
                1758-2652
                15 February 2021
                February 2021
                : 24
                : 2 ( doiID: 10.1002/jia2.v24.2 )
                : e25667
                Affiliations
                [ 1 ] NHC Key Laboratory of AIDS Immunology (China Medical University) National Clinical Research Center for Laboratory Medicine The First Affiliated Hospital of China Medical University Shenyang China
                [ 2 ] Key Laboratory of AIDS Immunology Chinese Academy of Medical Sciences Shenyang China
                [ 3 ] Key Laboratory of AIDS Immunology of Liaoning Province Shenyang China
                [ 4 ] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases Hangzhou China
                [ 5 ] Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
                [ 6 ] Beijing Youan Hospital Capital Medical University Beijing China
                [ 7 ] Chongqing Public Health Medical Center Chongqing China
                [ 8 ] Department of Infectious Diseases Shenzhen Third People’s Hospital Shenzhen China
                [ 9 ] Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill NC USA
                Author notes
                [*] [* ] Corresponding author: Sean Sylvia, Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. Tel: (919) 966‐6328. ( sean_sylvia@ 123456unc.edu )

                [*]

                These authors have contributed equally to the work.

                Author information
                https://orcid.org/0000-0002-1759-1041
                https://orcid.org/0000-0003-4303-7295
                https://orcid.org/0000-0001-7791-0131
                https://orcid.org/0000-0002-5045-9202
                https://orcid.org/0000-0002-3229-0108
                https://orcid.org/0000-0002-9524-8337
                https://orcid.org/0000-0002-6398-2107
                https://orcid.org/0000-0003-3654-8628
                https://orcid.org/0000-0002-2134-3809
                https://orcid.org/0000-0003-4330-6440
                https://orcid.org/0000-0001-8157-2227
                https://orcid.org/0000-0002-9574-6440
                https://orcid.org/0000-0002-4468-8404
                https://orcid.org/0000-0003-0137-0727
                https://orcid.org/0000-0001-9733-002X
                https://orcid.org/0000-0002-9445-5473
                https://orcid.org/0000-0003-0166-7846
                https://orcid.org/0000-0002-7008-9974
                https://orcid.org/0000-0002-9508-247X
                https://orcid.org/0000-0001-5333-8943
                Article
                JIA225667
                10.1002/jia2.25667
                7883476
                33586841
                2a017ba7-fefd-46bc-95d1-470e2a018364
                © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 24 June 2020
                : 09 January 2021
                : 13 January 2021
                Page count
                Figures: 1, Tables: 3, Pages: 10, Words: 9289
                Funding
                Funded by: National Natural Science Foundation of China , open-funder-registry 10.13039/501100001809;
                Award ID: 81872674
                Funded by: Mega‐Projects of National Science Research
                Award ID: 2012ZX10001006‐001‐010
                Award ID: 2017ZX10201101‐002‐007
                Award ID: 2018ZX10101001‐001‐0032018ZX10101001‐001‐003
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                February 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.7 mode:remove_FC converted:15.02.2021

                Infectious disease & Microbiology
                hiv,pre‐exposure prophylaxis,men who have sex with men,preference,regimen,switch

                Comments

                Comment on this article